Boston Scientific (BSX) stock surged 5.23% in pre-market trading on Wednesday following the release of its impressive second-quarter results and an upward revision of its full-year 2025 guidance. The medical device maker's performance was driven by robust demand for its heart devices and strong growth across all its business segments.

The company reported second-quarter revenue of $5.061 billion, surpassing analysts' expectations of $4.892 billion. Adjusted earnings per share (EPS) came in at $0.75, beating the consensus estimate of $0.72. This strong financial performance was underpinned by a 22.8% increase in reported net sales and a 17.4% rise in organic sales compared to the same period last year.

Boston Scientific's CEO, Mike Mahoney, attributed the quarter's success to "exceptional top-line performance, margin expansion, and strategic investment for future growth," crediting the global team's clinical and commercial excellence. The company's cardiovascular segment was particularly impressive, posting a remarkable 23.2% organic growth year-over-year. Key products driving this growth include the Farapulse Pulsed Field Ablation System and the Watchman FLX Pro Left Atrial Appendage Closure Device, both of which received regulatory approvals during the quarter.

In light of these strong results, Boston Scientific raised its full-year 2025 outlook. The company now expects adjusted EPS in the range of $2.95 to $2.99, up from its previous projection of $2.87 to $2.94. Additionally, it increased its full-year revenue growth forecast to 18-19%, up from the previous guidance of 15-17%. This optimistic outlook, coupled with the strong Q2 performance, has fueled investor confidence and driven the stock's significant pre-market rise.